U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767175) titled 'A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity' on Aug. 11.
Brief Summary: The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Study Start Date: Aug. 12
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: NNC0721-8060
NNC0721-8060 will be administered subcutaneously.
DRUG: Semaglutide
Semaglutide will be administered subcutaneously.
DRUG: Placebo
Placebo will be administered subcutaneously.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novo Nordisk A/S
Disclaimer: C...